India: India’s Patents Bill, 2005 - Is It TRIPS Compliant?

Last Updated: 31 March 2005
Article by Manoj Pillai

Finally, the Indian Parliament passed the Patents Bill (Bill No. 32-C of 2005). The Bill replaces the Patents Ordinance, 2004. For the first time in independent India’s history, national newspapers carried 4-column headline news covering ‘patents’. Patents Bill was also the topic of prime-time news in national TV channels. The ‘news value’ of the patents amendment bill was because of the political color it acquired. The Ordinance was strongly criticized by the Left Parties. The Patents Bill to substitute the Ordinance, therefore, created a national uproar. Finally, with several amendments mooted reportedly by the Left Parties, the Bill is passed. These amendments have considerably diluted the Ordinance. On a preliminary reading, the Bill (as passed) seems to fall short of TRIPS compliance. This memo highlights the major differences between the Ordinance and the Patents (Amendment) Bill, 2005 (hereinafter ‘the Bill’) and also enquires if it is TRIPS compliant!

The Bill redefines "inventive step"!

A new section 2(1)(ja) substituted the existing definition of ‘inventive step’ to mean "a feature of an invention that involves technical advances as compared to the existing knowledge or having economic significance or both and that makes the invention not obvious to a person skilled in the art".

This is an interesting attempt to ‘redefine’ one of the cardinal patentability criteria. ‘Inventive Step’ was originally defined in the Act to mean ‘a feature that makes the invention not obvious to a person skilled in the art’. An Explanatory note to Art. 27 (1) of the TRIPS Agreement states that ‘inventive step’ is synonymous with ‘non-obviousness’. There exists a plethora of judicial pronouncements on what constitute ‘non-obviousness’ as a criterion of patentability. Further, many national patent offices have practice guidelines explaining the fundamental propositions concerning what is not obvious to a ‘person of ordinary skill’ in a given technological art – so as to make an invention patentable.

The new wording of this Section does not reflect the distilled stock of knowledge on this subject. The wording ‘technical advances as compared to existing knowledge’ rather dilutes the very basis of obviousness/novelty requirements. If an invention is not adequately distinctive over prior art – it is not patentable. As such, what is the additional safeguard achieved by adding expressions that have the scope to make the whole definition vague and arbitrary?

The second phrase is ‘economic significance’. An invention to be non-obvious has to have ‘economic significance’ or ‘technical advances as compared to existing knowledge’! If so, what is the very purpose of the ‘utility’ criterion for patentability? By bringing ‘economic significance’ under the definition of ‘non-obviousness’ what has been fundamentally diluted is a cardinal principle of patent law! This new definition defeats the objectives behind the amendment. It interferes with the time-tested principles of patents law, and in that process has created a new definition that can lead to loose interpretations. It indeed falls short of the international legal practices on patentability – And arguably it is TRIPS non-compliant.

A new definition for ‘new inventions’

Unprecedented it is. The Bill retains the old definition of ‘invention’ in Section 2(1)(j). It however, added a definition on ‘new invention’. ‘New invention’ means any invention or technology which has not been anticipated by publication in any document or used in the country or elsewhere in the world before the date of filing of a patent application with complete specification, i.e. the subject matter has not fallen in public domain or that it does not form part of the state of the art.

Now the central question is this – whether the aforesaid definition of ‘new invention’ is an additional limitation on the definition of ‘invention’ under Section 2(1)(j). And if it is, does this amendment conform to Art. 27 of the TRIPS Agreement?

Here again, one can see a fundamental dilution of the tested principles of patent law. ‘Novelty’ of an invention is typically ascertained by testing if the invention has been anticipated by prior publication, or prior public working or prior public knowledge. There exists a huge stock of case laws on this. There are ways to ascertain this as well – of course with some levels of inherent limitations in carrying out prior art searches. But, redefining the ‘novelty’ requirement in the manner provided in the Bill deviates from the foundational norms on the test of novelty (to in turn ascertain patentability). This is another amendment that takes this Bill far away from the TRIPS Agreement. It puts unreasonable burden on a patent applicant to substantiate the novelty (and consequently patentability) of the claimed invention.

New Use – Redefined

The Ordinance amended Section 3(d) to ensure that what is not patentable is only mere new use. If a second medical indication of a known drug molecule passes the test that it is not a mere new use – as per the Ordinance it would have been patentable. The Bill drops this provision. Instead, it contains a rather too long explanation on the Section 3(d) exemption. According to this Section what is not patentable is:

"The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance"

"The mere discovery of any new property or new use for a known substance"

"The mere use of a known process, machine or apparatus – unless such process results in a new product or employs at least one new reactant"

Consequently, if a discovery of a new form of a known drug molecule (as for example) results in an enhancement of its known efficacy, it is patentable. Similarly, the mere discovery of a new use of a known substance is not patentable. The amended Section 3(d) when read in conjunction with Section 3(i) would ensure that all method of use inventions are unpatentable. A joint reading of the amended Section 3(d) and Section 3(i) is capable of keeping a major portion of pharmaceutical R&D outside the scope of patents.

The Bill provides an explanation that salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy. The phrase ‘differ significantly in properties with regard to efficacy’ is the final test of patentability as regards all inventions around a drug molecule. It seems this Explanation will keep a huge amount of research and development activity outside the scope of patentability – because the properties concerning efficacy (according to the Bill) will have an overriding effect over the standard tests of patentability when it comes to pharmaceutical inventions.

The objective behind such an elaborate explanation in Section 3(d) seems to be to check what the Indian generic drug makers allege as ‘evergreening’. However, this exclusion also seems to result in nonconformity of the amended law with the general mandate on patentability provided in the TRIPS Agreement.

Software Patents – new provision dropped

The Bill dropped the amendments to Section 3(k) as contained in the Ordinance. The Ordinance had introduced a new Section 3(ka) to exclude ‘mathematical methods, business methods or algorithms’ from the scope of patentability. As per Section 3(k) (as contained in the Ordinance) a computer program’s technical application to industry or a computer program in combination with hardware was patentable. What was not patentable was only computer program per se.

The Ordinance attempted to strike a balance between the arguments for and against software patents. It indeed brought the position close to the European Patent Office practices. That was a welcome change. Conventionally, there has been an argument in India that copyright is a preferred mode to protect computer software. That kept a huge amount of R&D activities involving computer software outside the scope of patents. India’s leading IT companies and industry associations favored a reasonable level of protection of computer software through patents. The Bill deviated from the Ordinance and brought back the original position. Now what is patentable in this area is – what is not computer program per se.

Mail Box Application can lead only to ‘Paper Patents’!

A Patent acquired through the Mail Box route is virtually of no use. The Bill says that a patentee who gets a patent through the Mail Box cannot institute infringement action against any enterprise that has been producing and marketing the patented product prior to January 1, 2005 and continues to manufacture the product as on the date of grant of the patent. Therefore a pharmaceutical company that has filed a patent application through the Mail Box route when eventually gets a patent for its product, it cannot file an infringement action against an Indian generic manufacturer who continues to manufacture the patented product. All what the patentee-company can ask for is ‘reasonable’ royalty! This provision takes away the very sanctity of Mail Box and transitional protection as envisaged in the TRIPS Agreement.

The above provision can be found in the newly inserted 3rd proviso to Section 11A. It is one of the amendments mooted during the recent political deliberations. This proviso undermines the whole concept of transitional protection under the TRIPS Agreement and definitely makes the Bill TRIPS non-compliant.

No More Representation – It is Opposition Before & After the Grant!

All grounds available for post-grant opposition have been made available to pre-grant opposition as well. The Bill thus envisages 2 oppositions! – First when the application is published, and second when a patent is granted. The post-grant opposition has to be initiated by an ‘interested person’. But any person can institute pre-grant opposition with the same ground as that of the post –grant opposition!

Interestingly the law allows a pre-grant opponent the right to be heard! There is, however, no provision in the Bill enabling the Applicant to counter the pre-grant opposition. That alone makes it a one-sided affair.

It is pertinent to highlight that the Rules framed under the Ordinance even mandated that the Pre-grant opponent has to file ‘a statement supported by evidence’. That made the pre-grant opposition a legal proceeding involving a process of adducing evidence. In a proceeding when the Opponent is allowed to adduce evidence against the patent applicant and if the patent applicant is given no chance to counter the evidence, it violates the fundamentals of administrative law & justice. That can possibly make this provision arbitrary and hence unconstitutional. Accordingly, the pre-grant opposition provision, which does not give the Patent Applicant the right to counter evidence adduced against him, may not stand the test of judicial scrutiny.

Compulsory License – grounds further expanded

The already elaborate Compulsory Licensing grounds got another boost. The newly inserted Section 92A(1) of the Bill expanded the scope of issuance of Compulsory Licenses for manufacture and export of patented pharmaceutical products to countries having insufficient manufacturing capacity in the pharmaceutical sector, if that country has by notification allowed such importation.

Concluding Remarks

As on date is the Indian Patents Act, 1970 (as amended by the Patents (Amendment) Bill, 2005 TRIPS complaint? This is the million-dollar question! While there cannot be a final answer to this until competent bodies address and decide on it, there are reasons to consider that it in fact is not TRIPS compliant. It has been reported in the national dailies that the Government will seek expert opinion on some issues pertaining to patentable subject matters. If so, presumably the final TRIPS compliance is yet to happen. It is time to wait and watch how the International community responds to India’s latest attempt on TRIPS compliance.

© Lex Orbis 2005

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions